J3389 — Topical administration, prademagene zamikeracel, per treatment
J3389 is a HCPCS Level II code for topical administration, prademagene zamikeracel, per treatment. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusE
Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
The CMS record for J3389
- Long descriptor
- Topical administration, prademagene zamikeracel, per treatment
- Short descriptor
- Topi adm prad zami per treat
- Added
- January 1, 2026
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J3389
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J3389 is not quite right, the correct code is very often within a few positions of it.
- J3374Injection, vancomycin hydrochloride (mylan) not therapeutically equivalent to j3373, 10 mg
- J3375Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mg
- J3376Injection, vancomycin hcl (hikma), not therapeutically equivalent to j3373, 10 mg
- J3379Injection, valproate sodium, 5 mg
- J3380Injection, vedolizumab, intravenous, 1 mg
- J3385Injection, velaglucerase alfa, 100 units
- J3386Injection, etuvetidigene autotemcel, per treatment
- J3387Injection, elivaldogene autotemcel, per treatment
- J3391Injection, atidarsagene autotemcel, per treatment
- J3392Injection, exagamglogene autotemcel, per treatment
- J3393Injection, betibeglogene autotemcel, per treatment
- J3394Injection, lovotibeglogene autotemcel, per treatment
- J3396Injection, verteporfin, 0.1 mg
- J3397Injection, vestronidase alfa-vjbk, 1 mg
- J3398Injection, voretigene neparvovec-rzyl, 1 billion vector genomes
- J3399Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes
Questions about J3389
What is HCPCS code J3389?
J3389 is a HCPCS Level II code for topical administration, prademagene zamikeracel, per treatment. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J3389?
The CMS HCPCS file marks J3389 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
How is J3389 paid under the physician fee schedule?
J3389 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).